PT - JOURNAL ARTICLE AU - Manuela Di Fusco AU - Jay Lin AU - Shailja Vaghela AU - Melissa Lingohr-Smith AU - Jennifer L Nguyen AU - Thomas Scassellati Sforzolini AU - Jennifer Judy AU - Alejandro Cane AU - Mary M Moran TI - COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies AID - 10.1101/2021.12.29.21268511 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.29.21268511 4099 - http://medrxiv.org/content/early/2021/12/31/2021.12.29.21268511.short 4100 - http://medrxiv.org/content/early/2021/12/31/2021.12.29.21268511.full AB - Introduction From July through October of 2021, several countries issued recommendations for increased COVID-19 vaccine protection for individuals with one or more immunocompromised (IC) conditions. It is critically important to understand the vaccine effectiveness (VE) of COVID-19 vaccines among IC populations as recommendations are updated over time in response to the evolving COVID-19 pandemic.Areas covered A targeted literature review was conducted to identify real-world studies that assessed COVID-19 VE in IC populations between December 2020 and September 2021. A total of 10 studies from four countries were identified and summarized in this review.Expert opinion/commentary VE of the widely available COVID-19 vaccines, including BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), Ad26.COV2.S (Janssen), and ChAdOx1 nCoV-19 (Oxford/AstraZeneca), ranged from 64%-90% against SARS-CoV-2 infection, 73%-84% against symptomatic illness, 70%-100% against severe illness, and 63%-100% against COVID-19-related hospitalization among the fully vaccinated IC populations included in the studies. COVID-19 VE for most outcomes in the IC populations included in these studies was lower than in the general populations. These findings provide preliminary evidence that the IC population requires greater protective measures to prevent COVID-19 infection and associated illness, hence should be prioritized while implementing recommendations of additional COVID-19 vaccine doses.Competing Interest StatementDisclosure statement: M Di Fusco, JL Nguyen, T Scassellati Sforzolini, J Judy, A Cane, and MM Moran are employees of Pfizer. S Vaghela is an employee of HealthEcon Consulting, Inc. and external consultant for Pfizer. M Lingohr-Smith and J Lin are employees of Novosys Health, which received funding support from Pfizer, Inc. for the preparation of this review article. Funding StatementFunding statement: This work was supported by Pfizer, Inc., which had a role in study design, data collection and the review of this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability statement: All data contained within this review were extracted from the published/preprint referenced articles and are available to the public. https://pubmed.ncbi.nlm.nih.gov/ https://www.medrxiv.org/ https://khub.net/